Risperidone long-acting injection in Schizophrenia Spectrum Illnesses compared to first generation depot antipsychotics in an outpatient setting in Canada

BMC Psychiatry

Richard Williams¹  Bree Zehm³  Laura Lammers² 

[1] Department of Psychiatry, Eric Martin Pavilion, Vancouver Island Health Authority, Victoria, Canada;Pharmacy Department, Nanaimo Regional General Hospital, Vancouver Island Health Authority, Nanaimo, Canada;Pharmacy Department, Royal Jubilee Hospital, Vancouver Island Health Authority, Victoria, Canada

关键词: Retrospective;    Treatment discontinuation;    Hospitalization;    Typical depot antipsychotic;    First generation depot antipsychotic;    Atypical depot antipsychotic;    Risperidone long acting injection;   

Others  :  1124038
DOI  :  10.1186/1471-244X-13-155

 received in 2012-08-20, accepted in 2013-05-23,  发布年份 2013

【 摘 要 】

Background

Depot formulations of antipsychotics provide a potential solution to the poor adherence to oral therapies in schizophrenia. However, there have been few comparative studies on the effectiveness and tolerability of first and second generation depot antipsychotics in a real clinical practice setting. The objectives of the present study were to compare safety and outcomes in patients with schizophrenia initiated on risperidone long-acting injection (RLAI) or first generation antipsychotic injections (FGAI) at a Mental Health Centre in British Columbia.

Methods

Data were collected by retrospective chart review of all active patients starting depot therapy who were ≥ 18 years of age, had received at least 3 injections of depot antipsychotic and had no prior clozapine treatment. Kaplan Meier survival curves were used to estimate probability of treatment discontinuation and hospitalization.

Results

A total of 70 RLAI and 102 FGAI patient charts were reviewed. At baseline patients in both groups had similar ages (39.7 and 42.7 years for RLAI and FGAI patients (p = 0.09), respectively) but FGAI patients had a longer time since diagnosis (13.6 vs. 9.85 years (p = 0.003)). Treatment retention at 18 months was 77% for RLAI and 86% for FGAI patients (p = 0.22) and 82% and 88% of patients, respectively (p = 0.28), had not been hospitalized. However, RLAI analyses were compromised by lack of long-term patient data. Concomitant medication utilization was similar in both groups except for anticholinergics which were used less frequently in RLAI patients (5.7% vs. 35.3%, p < 0.001). Adverse event frequency was also similar except for extrapyramidal symptoms (EPS) which were more common in FGAI patients (52.9% vs. 17.0% for RLAI (p < 0.001)).

Conclusions

There was no apparent difference in treatment discontinuation or hospitalization between RLAI and FGAI treated patients, although analysis was compromised by low patient numbers. However, decreased EPS with RLAI may offer a significant clinical benefit to patients with schizophrenia.

【 授权许可】

   
2013 Lammers et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Van Os J, Kapur S: Schizophrenia. Lancet 2009, 374:635-645.
• [2]Goldner EM, Hsu L, Waraich P, Somers JM: Prevalence and incidence studies of schizophrenic disorders: a systematic review of the literature. Can J Psychiatry 2002, 47:833-843.
• [3]Warner R: Schizophrenia: a 100-year retrospective. Am J Psychiatry 1995, 152:1693-1695.
• [4]Goeree R, O‘Brien BJ, Goering P, Blackhouse G, Agro K, Rhodes A, Watson J: The economic burden of schizophrenia in Canada. Can J Psychiatry 1999, 44:464-472.
• [5]Llorca PM: Partial compliance in schizophrenia and the impact on patient outcomes. Psychiatry Res 2008, 161:235-247.
• [6]Leucht S, Heres S: Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia. J Clin Psychiatry 2006, 67(Suppl 5):3-8.
• [7]Fleischhacker WW, Oehl MA, Hummer M: Factors influencing compliance in schizophrenia patients. J Clin Psychiatry 2003, 64(Suppl 16):10-13.
• [8]Perkins DO: Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 2002, 63:1121-1128.
• [9]Turner MS, Stewart DW: Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses. J Psychopharmacol 2006, 20(6):20-37.
• [10]Taylor D: Psychopharmacology and adverse effects of antipsychotic long-acting injections: a review. Br J Psychiatry 2009, 195:S13-S19.
• [11]Kennedy E, Song F, Hunter R, Clarke A, Gilbody S: Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database Syst Rev 2000., 2CD000440
• [12]Leucht S, Kissling W, Davis JM: Second-generation antipsychotics for schizophrenia: can we resolve the conflict? Psychol Med 2009, 39:1591-1602.
• [13]Correll CU, Leucht S, Kane JM: Lower risk for tardive dyskinesia associated with second-generation antipsychotics: A systematic review of 1-year studies. Am J Psychiatry 2004, 161:414-425.
• [14]Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K: Long-acting injectable risperidone; efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003, 160:1125-1132.
• [15]Fleischhacker WW, Eerdekens M, Karcher K, Remington G, Llorca PM, Chrzanowski W, Martin S, Gefvert O: Treatment of schizophrenia with long-acting injectable risperidone: A 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 2003, 64:1250-1257.
• [16]Branch PR: Abnormal involuntary movement scale (AIMS). Early Clin Eval Unit Intercom 1975, 4:3-6.
• [17]Simpson GM, Angus JWS: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970, 212:11-19.
• [18]Schooler NR, Kane JM: Research diagnosis for tardive dyskinesia (letter). Arch Gen Psychiatry 1982, 39:486-487.
• [19]Gardner DM, Murphy AL, O‘Donnell H: International consensus study of antipsychotic dosing. Am J Psychiatry 2010, 167:686-963.
• [20]Haro JM, Suarez D, Novick D, Brown J, Usall J, Naber D, SOHO Study Group: Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: Observational versus randomized studies results. Eur Neuropsychopharmacol 2007, 17:235-244.
• [21]Peuskens J, Olivares JM, Pecenak J, Tuma I, bij de Weg H, Eriksson L, Resseler S, Akhras K, Jacobs A: Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries. Curr Med Res Opin 2010, 26:501-509.
• [22]Haddad PM, Taylor M, Niaz OS: First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: systematic review of randomized controlled trials and observational studies. Brit J Psychiatry 2009, 195:S20-S28.
• [23]Virit O, Altindag A, Bulbul F, Savas HA, Dalkilic A: Long-acting typical and atypical antipsychotics in treatment of schizophrenia: a retrospective comparison. Bull Clin Psychopharmacol 2009, 19:119-127.
• [24]Olfson M, Marcus SC, Ascher-Svanum H: Treatment of schizophrenia with long-acting fluphenazine, haloperidol or risperidone. Schizophr Bull 2007, 33:1379-1387.
• [25]Zhu B, Ascher-Svanum H, Faries DE, Correll CU, Kane JM: Cost of antipsychotic polypharmacy in the treatment of schizophrenia. BMC Psychiatry 2008, 8:19. BioMed Central Full Text
• [26]Barnes TRE, Paton C: Antipsychotic polypharmacy in schizophrenia: benefits and risks. CNS Drugs 2011, 25:383-399.
• [27]Lasser RA, Bossie CA, Gharabawi GM, Turner M: Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone. Eur Psychiatry 2004, 19:219-225.
• [28]Turner M, Eerdekens E, Jacko M, Eerdekens M: Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics. Int Clin Psychopharmacol 2004, 19:241-249.
• [29]Addington D, Bouchard RH, Goldberg J, Honer B, Malla A, Norman R, Tempier R: Clinical practice guidelines: treatment of schizophrenia. Can J Psychiatry 2005, 50:7s-57s.
• [30]Casey DE: Implications of the CATIE trial on treatment: Extrapyramidal symptoms. CNS Spectr 2006, 11(Suppl 7):25-31.
• [31]Pierre JM: Extrapyramidal symptoms with atypical antipsychotics: incidence, prevention, and management. Drug Saf 2005, 28:191-208.